Accessible & Effective treatment for depression



NeuroQore, Inc., is set to commercialize a new patented monophasic repetitive transcranial magnetic stimulation (rTMS) system with an improved remission rate. The first unit of the NeuroQore rTMS system was installed at the Royal Ottawa Mental Health Centre in July 2015 and successfully passed tolerability testing on healthy volunteers in a pilot project. The company is now in the midst of recruiting patients for the next round of testing. Preliminary clinical data is promising and has prompted installation of more units. 


What Makes NeuroQore Different?

NeuroQore, Inc. offers the world's first monophasic rTMS therapy system. This system is a rapid and serious alternative for major depressive disorder, acute depression, and suicide. NeuroQore, Inc. offers dramatically reduced treatment times and immediate symptom relief. NeuroQore's unique approach allows patients to achieve remission within a few days.



Major depressive disorder affects approximately 4.7% world population annually and 1 in 3 do not recover with medications or therapy. For treatment-resistant depression (TRD), electroconvulsive therapy (ECT) is effective (60-70% remission), but hampered by the need for anesthesia, significant cognitive side effects, and high stigma. Less than 1% of TRD population receive ECT annually.


Repetitive transcranial magnetic stimulation (rTMS) is an emerging therapeutic brain stimulation technique that does not require anesthesia, has no cognitive side effects, and is widely accepted by patients. rTMS is currently administered by a technician or nurse in an outpatient clinical setting. The potency and efficacy of conventional biphasic rTMS (45-55% response, 30-35% remission) falls between medications and ECT, but rTMS offers the advantages of high tolerability and accessibility.

NeuroQore monophasic rTMS system with an improved remission rate has potential to be a disruptive innovation that results in improved health care worldwide. NeuroQore is looking to effectively integrate into existing health-care facilities and coordinated with ongoing treatments as a complement to medications and therapy.


COntact us.


CANADA & USA: 1 833 733 6787

international: 613 264 7048

Thank you for visiting

Please take a moment to fill out this survey!
Name *
Do you currently offer rTMS treatment?
What is your current knowledge level regarding rTMS treatment and technology?
What is your current interest level in rTMS treatment and technology?
Are you planning on acquiring a new rTMS system?
Did you know that common rTMS manufacturers including Neuronetics, Magstim, Magventure, and Brainsway only offer biphasic rTMS technology?
Did you know NeuroQore, Inc. offers monophasic rTMS technology with improved clinical efficacy?
Would you like to demo a NeuroQore, Inc. unit and speak to a representative?